Primary:* Study the influence of sleep on motor performance and cognitive flexibility in PD patients.* Compare and describe in more detail, the differences in the influence of sleep in patients that report to experience SB and those who do not.…
Source
Brief title
Condition
- Movement disorders (incl parkinsonism)
Synonym
Research involving
Sponsors and support
Intervention
No registrations found.
Outcome measures
Primary outcome
* The difference between post-nap and pre-nap performance on the pegboard
dexterity test.
Secondary outcome
Secondary:
* The difference between post-nap and pre-nap performance on the task-switching
task.
Other:
Objective:
* The difference between post-nap and pre-nap performance on the finger
tappingtask.
* The difference between post-night sleep and pre-night sleep performance on
the motor tasks (pegboard dexterity test and finger tapping).
* The difference between post-night sleep and pre-night sleep performance on
the task-switching task.
* Sleep outcomes as measured by polysomnography
Subjective:
* The difference between post-nap and pre-nap ratings on subjective functioning
and mood.
* The difference between post-night sleep and pre-night sleep ratings on
subjective functioning and mood.
Background summary
Sleep disorders are highly prevalent among patients with Parkinson*s disease
(PD). However, there are also reports of PD patients experiencing a beneficial
effect of sleep. Upon awaking in the morning they experience an improved
mobility as if they are in a medication induced *on* state, contrary to what
would be expected after a night without medication. This intriguing phenomenon
is known as sleep benefit (SB). Some PD patients are even able to delay or skip
their morning dose of medication because of SB . Also cases of SB after an
afternoon nap are known. Most research on SB is questionnaire based. Subjects
are asked for their subjective judgement whether they experience SB or not. The
prevalence of SB, found with these questionnaires is quite high; 33-55% of the
PD patients reports to experience SB. More objective measures of SB, on the
other hand, are scarce. In this study we will use different tasks on motor
functioning and cognitive flexibility to study the influence of sleep on
functioning of PD patients.
Study objective
Primary:
* Study the influence of sleep on motor performance and cognitive flexibility
in PD patients.
* Compare and describe in more detail, the differences in the influence of
sleep in patients that report to experience SB and those who do not.
Secondary:
* To assess the correlation of sleep related changes in motor functioning and
cognitive flexibility, with quality and characteristics of the preceding period
of sleep.
* To assess the correlation of subjective ratings on mood and motor
functioning, with the degree of sleep related changes in motor functioning and
cognitive flexibility.
Study design
The evening before the experimental day, subjects come to the hospital in the
*off* state (no medication taken in the last 8 hours). First they will train
the pegboard dexterity task (PDT), the finger tapping task (FTT) and the
task-switching task (TST), followed by a test session. All test sessions
include the PDT, FTT, TST and subjective rating scales on motor functioning and
mood.
Subjects spend the night in the hospital. Patients are allowed to take their
usual PD medication before the night. However, on the experimental day,
patients do not take their medication. At awakening in the morning, a test
session is completed.
In the morning on the experimental day, a neuropsychological test battery is
completed.
In the early afternoon on the experimental day, all subjects take an afternoon
nap directly followed by a test session. Baseline measures are taken either
before the nap, or after the post sleep measures, after an additional period of
active wakefulness, when possible SB effects have disappeared. The moment of
baseline examination is counterbalanced in all groups.
Study burden and risks
Patients may experience reduced mobility due to temporary cessation of
Parkinson medication.
Reinier Postlaan 4
Nijmegen 6525 GC
NL
Reinier Postlaan 4
Nijmegen 6525 GC
NL
Listed location countries
Age
Inclusion criteria
Idiopatic Parkinson's disease (patients)
Hoehn & Yahr stage II-III (patients)
able to take an afternoon nap (patients and controls)
Exclusion criteria
Neurological diease (for patients; other than Parkinson's disease)
Current psychiatric diagnosis (including depression)
MMSE < 24 (patients), MMSE < 28 (controls)
color blindness
Chronic daily use of sleep medication
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL42411.091.12 |